Company

SomaServe, Ltd

SomaServe develops genetic nanomedicines to deliver nucleic acid therapies to tissues and cells.

About

Founded in 2018 and based in Cambridge, UK, SomaServe develops genetic therapies using its polyNaut® platform for delivering mRNA, siRNA and gene-editing treatments. Its work is aimed at pharmaceutical companies and research institutions. In November 2023, the company raised USD 25.00 mn in Series A funding led by 4BIO Capital Partners, Cystic Fibrosis Foundation and Eli Lilly & Company, among others. Francesca Crawford is CEO.

3Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in